DF
MCID: DNG005
MIFTS: 64

Dengue Virus (DF)

Categories: Blood diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Dengue Virus

MalaCards integrated aliases for Dengue Virus:

Name: Dengue Virus 57
Dengue Fever, Protection Against 57 13 6
Dengue Virus, Susceptibility to 57 29 40
Dengue Fever 59 73
Dengue Virus Infection 59
Df 59

Characteristics:

Orphanet epidemiological data:

59
dengue fever
Prevalence: >1/1000 (Worldwide),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


Summaries for Dengue Virus

OMIM : 57 Dengue virus is a flavivirus belonging to the family Flaviviridae. Its principal vector is Aedes aegypti, a highly urbanized, daytime-biting mosquito that breeds in stored water. There are 4 antigenetically variant serotypes of dengue virus, DEN-1 to DEN-4, and type-specific immunity against one serotype cannot block infection with another serotype. Disease manifestations following dengue infection range from subclinical infection to severe and fatal disease, with age, gender, genotype, immunologic status, and flavivirus infection history of the host all influencing disease severity. Primary infection is mainly associated with dengue fever (DF). Symptoms of DF typically appear 4 to 7 days after the mosquito bite and include high fever, headache, retroocular pain, conjunctival changes, and facial flushing. Although primary dengue infections are mostly recovered, a secondary infection with a different serotype of the virus leads to the complex condition of dengue hemorrhagic fever (DHF) with plasma leakage and thrombocytopenia or a more fatal condition, dengue shock syndrome (DSS). High fever, hemorrhagic phenomenon, hepatomegaly, and circulatory failure are mainly associated with DHF. Hemorrhages in DHF are seen in skin, subcutaneous tissues, heart, liver, and gastrointestinal tract. An estimated 50 to 100 million illnesses due to dengue infection occur annually, including 250,000 to 500,000 cases of DHF and 24,000 deaths. About 2.5 billion people are estimated to be at risk, particularly those living in tropical and subtropical areas of Asia and Latin America (reviews by Faheem et al. (2011), Whitehorn and Simmons (2011), and Guzman et al. (2010)). (614371)

MalaCards based summary : Dengue Virus, also known as dengue fever, protection against, is related to viral infectious disease and west nile virus, and has symptoms including fever and pruritus. An important gene associated with Dengue Virus is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Ketotifen and Histamine have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and endothelial, and related phenotypes are nausea and vomiting and hypotension

CDC : 3 With more than one-third of the world’s population living in areas at risk for infection, dengue virus is a leading cause of illness and death in the tropics and subtropics. As many as 400 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are not yet any vaccines to prevent infection with dengue virus and the most effective protective measures are those that avoid mosquito bites. When infected, early recognition and prompt supportive treatment can substantially lower the risk of medical complications and death.

Wikipedia : 76 Dengue virus (DENV) is the cause of dengue fever. It is a mosquito-borne single positive-stranded RNA... more...

Related Diseases for Dengue Virus

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)
# Related Disease Score Top Affiliating Genes
1 viral infectious disease 31.6 CD209 DDX58 IFIH1
2 west nile virus 31.3 CD209 DDX58 EXOC1 IFIH1 IFITM1 IFITM2
3 japanese encephalitis 30.7 CD209 DDX58
4 encephalitis 30.7 CD209 DDX58 RPSA RSAD2
5 chikungunya 30.7 DDX58 OAS3 RSAD2
6 noonan syndrome 3 30.6 DDX58 NRBP1 RSAD2 STAT2
7 tick-borne encephalitis 29.9 CD209 OAS3
8 rift valley fever 29.9 CD209 IFITM3
9 hepatitis 29.8 CLDN1 DDX58 HAVCR1
10 noonan syndrome 2 29.8 DDX58 STAT2
11 measles 29.7 CD209 DDX58 IFIH1 STAT2
12 herpes simplex 29.7 CD209 DDX58 IFIH1
13 influenza 29.6 DDX58 IFIH1 IFITM1 IFITM2 IFITM3 RSAD2
14 hepatitis c virus 29.1 CLDN1 DDX58 IFIH1 IFITM1 RSAD2
15 dengue disease 12.3
16 dengue hemorrhagic fever 11.8
17 dengue shock syndrome 11.7
18 asymptomatic dengue 11.7
19 kyasanur forest disease 11.1
20 noonan syndrome 5 10.6
21 hemorrhagic fever 10.5
22 zika fever 10.2
23 zika virus infection 10.2
24 thrombocytopenia 10.2
25 yellow fever 10.2
26 marburg hemorrhagic fever 10.2 CD209 STAT2
27 kawasaki disease 10.2
28 guillain-barre syndrome 10.2
29 singleton-merten syndrome 10.2 DDX58 IFIH1
30 appendicitis 10.1
31 malaria 10.1
32 form agnosia 10.1
33 agnosia 10.1
34 neutropenia 10.1
35 thrombosis 10.1
36 cardiac tamponade 10.1
37 hepatitis a 10.1
38 acute kidney tubular necrosis 10.1
39 acute pancreatitis 10.1
40 pancreatitis 10.1
41 acute disseminated encephalomyelitis 10.1
42 st. louis encephalitis 10.1
43 myelitis 10.1
44 transverse myelitis 10.1
45 microphthalmia with limb anomalies 10.0 OAS3 STAT2
46 asthma 10.0
47 diabetic foot ulcers 10.0
48 carcinoma showing thymus-like differentiation 10.0
49 myoclonus 10.0
50 systemic lupus erythematosus 10.0

Graphical network of the top 20 diseases related to Dengue Virus:



Diseases related to Dengue Virus

Symptoms & Phenotypes for Dengue Virus

Clinical features from OMIM:

614371

Human phenotypes related to Dengue Virus:

59 32 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002017
2 hypotension 59 32 occasional (7.5%) Occasional (29-5%) HP:0002615
3 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
4 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
5 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
6 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
7 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
8 pruritus 59 32 frequent (33%) Frequent (79-30%) HP:0000989
9 thrombocytopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001873
10 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
11 diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002014
12 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
13 skin rash 59 32 frequent (33%) Frequent (79-30%) HP:0000988
14 bruising susceptibility 59 32 occasional (7.5%) Occasional (29-5%) HP:0000978
15 gingival bleeding 59 32 occasional (7.5%) Occasional (29-5%) HP:0000225
16 petechiae 59 32 occasional (7.5%) Occasional (29-5%) HP:0000967
17 lethargy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001254
18 headache 59 32 hallmark (90%) Very frequent (99-80%) HP:0002315
19 cerebral hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0001342
20 leukopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001882
21 hypoproteinemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003075
22 cardiorespiratory arrest 59 32 occasional (7.5%) Occasional (29-5%) HP:0006543

UMLS symptoms related to Dengue Virus:


fever, pruritus

GenomeRNAi Phenotypes related to Dengue Virus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.03 RPSA
2 Decreased viability GR00221-A-2 10.03 NRBP1
3 Decreased viability GR00221-A-3 10.03 NRBP1
4 Decreased viability GR00240-S-1 10.03 RPSA
5 Decreased viability GR00381-A-1 10.03 IFITM1 RPSA
6 Decreased viability GR00402-S-2 10.03 C19orf66 CD209 CLDN1 CLEC5A DDX58 EXOC1
7 no effect GR00402-S-1 9.58 C19orf66 CD209 CLDN1 CLEC5A DDX58 EXOC1

Drugs & Therapeutics for Dengue Virus

Drugs for Dengue Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 26)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
2
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
3 Anti-Allergic Agents Phase 4
4
Histamine Phosphate Phase 4 51-74-1 65513
5 Antipruritics Phase 4
6 Histamine H1 Antagonists Phase 4
7 Neurotransmitter Agents Phase 4
8 Dermatologic Agents Phase 4
9 Histamine Antagonists Phase 4
10 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
11 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
13 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
14
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
15 Antibodies Phase 1, Phase 2,Phase 2,Not Applicable
16 Immunoglobulins Phase 1, Phase 2,Phase 2,Not Applicable
17
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
18
Aluminum sulfate Approved Phase 1 10043-01-3
19 Adjuvants, Immunologic Phase 1
20 Anti-Ulcer Agents Phase 1
21 Antacids Phase 1
22 Gastrointestinal Agents Phase 1
23 Antibodies, Monoclonal Phase 1
24
Ivermectin Approved, Investigational, Vet_approved Not Applicable 70288-86-7 6474909
25
Albendazole Approved, Vet_approved Not Applicable 54965-21-8 2082
26
Mebendazole Approved, Vet_approved Not Applicable 31431-39-7 4030

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) Active, not recruiting NCT02555072 Phase 4
3 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Unknown status NCT01374516 Phase 3
4 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
5 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
6 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
7 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
8 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
9 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
10 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults Recruiting NCT03342898 Phase 3
11 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
12 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
13 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
14 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine Active, not recruiting NCT03525119 Phase 3
15 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3 TDV Placebo
16 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) Active, not recruiting NCT03341637 Phase 3
17 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
18 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
19 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
20 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
21 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
22 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
23 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
24 A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children Completed NCT01843621 Phase 1, Phase 2
25 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
26 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
27 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
28 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
29 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
30 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
31 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
32 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore Completed NCT02425098 Phase 2
33 Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults Recruiting NCT02421367 Phase 1, Phase 2
34 Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults Recruiting NCT03746015 Phase 2
35 A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan Recruiting NCT03485144 Phase 2
36 Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh Active, not recruiting NCT02678455 Phase 2
37 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Active, not recruiting NCT02824198 Phase 2
38 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule Active, not recruiting NCT02623725 Phase 2
39 Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age Active, not recruiting NCT02628444 Phase 2
40 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Active, not recruiting NCT03110770 Phase 2
41 Safety and Immunogenicity of Takeda's TDV in Healthy Children Active, not recruiting NCT02948829 Phase 2
42 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Not yet recruiting NCT02741128 Phase 2
43 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
44 Safety and Immune Response to an Investigational Dengue Type 2 Vaccine Completed NCT01073306 Phase 1
45 Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine Completed NCT01436422 Phase 1
46 Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine Completed NCT01072786 Phase 1
47 Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults Completed NCT01931176 Phase 1
48 Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine Completed NCT02684383 Phase 1
49 Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine Completed NCT01084291 Phase 1
50 Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine Completed NCT01506570 Phase 1

Search NIH Clinical Center for Dengue Virus

Genetic Tests for Dengue Virus

Genetic tests related to Dengue Virus:

# Genetic test Affiliating Genes
1 Dengue Virus, Susceptibility to 29 CD209

Anatomical Context for Dengue Virus

MalaCards organs/tissues related to Dengue Virus:

41
Testes, Liver, Endothelial, Skin, T Cells, Monocytes, Heart

Publications for Dengue Virus

Articles related to Dengue Virus:

(show top 50) (show all 2556)
# Title Authors Year
1
In situ removal of consensus dengue virus envelope protein domain III fused to hydrophobin in Pichia pastoris cultures. ( 30240632 )
2019
2
Administration of plasmacytoid dendritic cell-stimulative lactic acid bacteria is effective against dengue virus infection in mice. ( 30365042 )
2019
3
Dengue virus potentially promotes migratory responses on endothelial cells by enhancing pro-migratory soluble factors and miRNAs. ( 30367889 )
2019
4
Dengue Virus IgM Serotyping by ELISA with Recombinant Mutant Envelope Proteins. ( 30387417 )
2019
5
Seroprevalence of West Nile and dengue virus in the human population of the Bolivian Chaco. ( 30118540 )
2019
6
Raman spectroscopy based differentiation of typhoid and dengue fever in infected human sera. ( 30114579 )
2019
7
Seroprevalence of dengue fever and the associated sociodemographic, clinical, and environmental factors in Makkah, Madinah, Jeddah, and Jizan, Kingdom of Saudi Arabia. ( 30244133 )
2019
8
Implications of meteorological and physiographical parameters on dengue fever occurrences in Delhi. ( 30292120 )
2019
9
Comparison of reverse-transcriptase qPCR and droplet digital PCR for the quantification of dengue virus nucleic acid. ( 29398345 )
2018
10
Joint ancestry and association test indicate two distinct pathogenic pathways involved in classical dengue fever and dengue shock syndrome. ( 29447178 )
2018
11
Ex Vivo ELISpot Assay to Investigate Dengue Virus Specific T-Cell Responses. ( 29956183 )
2018
12
Potent Neutralization Ability of a Human Monoclonal Antibody Against Serotype 1 Dengue Virus. ( 29928270 )
2018
13
Dynamic remodeling of lipids coincides with dengue virus replication in the midgut of Aedes aegypti mosquitoes. ( 29447265 )
2018
14
Long-term stability of antibody responses elicited by Dengue virus envelope DIII-based DNA vaccines. ( 29923817 )
2018
15
Dengue Virus Induces the Release of sCD40L and Changes in Levels of Membranal CD42b and CD40L Molecules in Human Platelets. ( 29976871 )
2018
16
Renal manifestations of dengue virus infections. ( 29414180 )
2018
17
Aedes anphevirus (AeAV): an insect-specific virus distributed worldwide in <i>Aedes aegypti</i> mosquitoes that has complex interplays with <i>Wolbachia</i> and dengue virus infection in cells. ( 29950416 )
2018
18
Erratum: Publisher Correction: A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus. ( 29424838 )
2018
19
Immune response-related genes associated to blocking midgut dengue virus infection in Aedes aegypti strains that differ in susceptibility. ( 29389079 )
2018
20
First detection of dengue virus in the saliva of immunocompetent murine model. ( 29412340 )
2018
21
Proposing drug fragments for dengue virus NS5 protein. ( 29945503 )
2018
22
C5a receptor targeting of partial non-structural protein 3 of dengue virus promotes antigen-specific IFN-I^-producing T-cell responses in a mucosal dengue vaccine model. ( 29397905 )
2018
23
Complete Genome Sequence of Dengue Virus Serotype 2, Asian/American Genotype, Isolated from the Urine of a Venezuelan Child with Hemorrhagic Fever in 2016. ( 29903824 )
2018
24
Complete Genome Sequence Analysis of an Imported Dengue Virus Serotype 1 Strain from Myanmar. ( 29976608 )
2018
25
Post Dengue Fever Epidural abscess with or without Spondylodiscitis-a Case series of 8 patients in a single season in a single Centre: Do the dengue has a predilection for the Neural tissue? ( 29979359 )
2018
26
Validation of POCKITa8c Dengue Virus Reagent Set for Rapid Detection of Dengue Virus in Human Serum on a Field-Deployable PCR System. ( 29436418 )
2018
27
Cloning and Expression of NS3 Gene of Pakistani Isolate Type 2 Dengue Virus. ( 29978123 )
2018
28
Development of peptide-based chemiluminescence enzyme immunoassay (CLEIA) for diagnosis of dengue virus infection in human. ( 29966589 )
2018
29
Competitive suppression of dengue virus replication occurs in chikungunya and dengue co-infected Mexican infants. ( 29970133 )
2018
30
Complete Coding Sequences of Five Dengue Virus Type 2 Clinical Isolates from Venezuela Obtained through Shotgun Metagenomics. ( 29930056 )
2018
31
Transcytosis Involvement in Transport System and Endothelial Permeability of Vascular Leakage during Dengue Virus Infection. ( 29419739 )
2018
32
Selective Tropism of Dengue Virus for Human Glycoprotein Ib. ( 29426910 )
2018
33
Spatial-Temporal Analysis of Dengue Fever and Hemorrhagic Fever in Mexico from 1995-2015. ( 29402463 )
2018
34
Inhibitory effect of the green tea molecule EGCG against dengue virus infection. ( 29429035 )
2018
35
Molecular characterization of an imported dengue virus serotype 4 isolate from Thailand. ( 29948381 )
2018
36
Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1). ( 29409531 )
2018
37
Longitudinally extensive transverse myelitis following dengue virus infection: A rare entity. ( 29536963 )
2018
38
Posaconazole inhibits dengue virus replication by targeting oxysterol-binding protein. ( 29981375 )
2018
39
Travel-acquired Scrub Typhus Infection Masked by Dengue Fever in a Patient from Nonendemic Area. ( 29910575 )
2018
40
Seroprevalence of Dengue Virus, West Nile Virus, Chikungunya Virus, and Zika Virus in International Travelers Attending a Travel and Migration Center in 2015-2017, Southern Italy. ( 29683399 )
2018
41
Arthropod EVs mediate dengue virus transmission through interaction with a tetraspanin domain containing glycoprotein Tsp29Fb. ( 29946031 )
2018
42
Cultured ELISpot Assay to Investigate Dengue Virus Specific T-Cell Responses. ( 29956182 )
2018
43
Ocular manifestations of emerging arboviruses: Dengue fever, Chikungunya, Zika virus, West Nile virus, and yellow fever. ( 29929827 )
2018
44
Imported case of Dengue virus 3 genotype I in Rio de Janeiro state, Brazil. ( 29947712 )
2018
45
Dengue virus serotype distribution based on serological evidence in pediatric urban population in Indonesia. ( 29953438 )
2018
46
Anaplerotic Role of Glucose in the Oxidation of Endogenous Fatty Acids during Dengue Virus Infection. ( 29404419 )
2018
47
The spatial and temporal scales of local dengue virus transmission in natural settings: a retrospective analysis. ( 29394906 )
2018
48
Dengue virus infection among long-term travelers from the Netherlands: A prospective study, 2008-2011. ( 29415063 )
2018
49
The epidemiological characteristics and molecular phylogeny of the dengue virus in Guangdong, China, 2015. ( 29967414 )
2018
50
Acute Pancreatitis in Dengue Fever. ( 29076099 )
2018

Variations for Dengue Virus

ClinVar genetic disease variations for Dengue Virus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CD209 CD209, -336A-G single nucleotide variant protective,risk factor

Expression for Dengue Virus

Search GEO for disease gene expression data for Dengue Virus.

Pathways for Dengue Virus

GO Terms for Dengue Virus

Cellular components related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.4 CD209 CLDN1 CLEC5A DDX58 EXOC1 IFITM1

Biological processes related to Dengue Virus according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 viral entry into host cell GO:0046718 9.88 CD209 CLDN1 CLEC5A HAVCR1 MRC1 RPSA
2 type I interferon signaling pathway GO:0060337 9.8 IFITM1 IFITM2 IFITM3 OAS3 RSAD2 STAT2
3 response to virus GO:0009615 9.8 DDX58 IFIH1 IFITM1 IFITM2 IFITM3 OAS3
4 cellular response to interferon-gamma GO:0071346 9.78 CLDN1 LGALS9 MRC1
5 response to interferon-gamma GO:0034341 9.73 C19orf66 IFITM1 IFITM2 IFITM3
6 positive regulation of interleukin-6 secretion GO:2000778 9.71 DDX58 IFIH1 LGALS9
7 negative regulation of viral entry into host cell GO:0046597 9.7 IFITM1 IFITM2 IFITM3
8 viral process GO:0016032 9.7 CD209 CLDN1 CLEC5A DDX58 EXOC1 HAVCR1
9 positive regulation of tumor necrosis factor secretion GO:1904469 9.69 DDX58 IFIH1 LGALS9
10 response to interferon-alpha GO:0035455 9.65 IFITM1 IFITM2 IFITM3
11 response to interferon-beta GO:0035456 9.63 IFITM1 IFITM2 IFITM3
12 negative regulation of viral genome replication GO:0045071 9.63 C19orf66 IFITM1 IFITM2 IFITM3 OAS3 RSAD2
13 negative regulation of type I interferon production GO:0032480 9.62 DDX58 IFIH1
14 positive regulation of interferon-beta production GO:0032728 9.62 DDX58 IFIH1
15 cellular response to exogenous dsRNA GO:0071360 9.61 DDX58 IFIH1
16 positive regulation of interferon-alpha production GO:0032727 9.6 DDX58 IFIH1
17 positive regulation of interferon-alpha secretion GO:1902741 9.59 DDX58 IFIH1
18 positive regulation of response to cytokine stimulus GO:0060760 9.58 DDX58 IFIH1
19 detection of virus GO:0009597 9.58 DDX58 IFIH1
20 positive regulation of interferon-beta secretion GO:0035549 9.57 DDX58 IFIH1
21 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.56 DDX58 IFIH1
22 regulation of type III interferon production GO:0034344 9.55 DDX58 IFIH1
23 defense response to virus GO:0051607 9.32 C19orf66 DDX58 EXOC1 IFIH1 IFITM1 IFITM2
24 immune system process GO:0002376 10.04 CD209 CLEC5A DDX58 IFIH1 IFITM1 OAS3
25 innate immune response GO:0045087 10.02 CD209 CLEC5A DDX58 IFIH1 IFITM1 IFITM2

Molecular functions related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded RNA binding GO:0003725 9.33 DDX58 IFIH1 OAS3
2 mannose binding GO:0005537 9.32 CD209 MRC1
3 carbohydrate binding GO:0030246 9.26 CD209 CLEC5A LGALS9 MRC1
4 virus receptor activity GO:0001618 9.1 CD209 CLDN1 CLEC5A HAVCR1 MRC1 RPSA
5 protein binding GO:0005515 10.13 C19orf66 CD209 CLDN1 CLEC5A DDX58 EXOC1

Sources for Dengue Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....